

About Technology Catalysts International



Technology Catalysts International (TCI) was founded in 1979 to provide consulting services that satisfy the licensing and business research needs of the pharmaceutical and chemical industries. We specialize in technology licensing, technology assessment, and technology portfolio management. The firm is headquartered in Falls Church, Virginia, a suburb of Washington D.C. Our global network includes offices in Japan, Korea, India, Argentina, the United Kingdom, Germany, China, and the Czech Republic.

Our research staff is composed of professionals with backgrounds in a variety of technical disciplines with additional expertise in international marketing, licensing, finance, and business development. The breadth of our experience assures clients of high quality, actionable information, and complete coverage on topics of interest.

TCI's core consulting services are based on continuous monitoring of global technology development. We provide consulting and technology transfer services to leading product developers and manufacturers in North and South America, Europe, and Asia. Our client base consists of small, medium, and large corporations.

For more information on our services and capabilities, please visit our website at:

www.technology-catalysts.com

Worldwide contacts for additional information

World Headquarters

Ajay Rastogi
Vice President
Technology Catalysts International Corporation
605 Park Avenue
Falls Church, VA 22046 USA
Telephone: (703) 531-0257
Facsimile: (703) 237-0042
E-mail: arastogi@technology-catalysts.com
Website: www.technology-catalysts.com

Europe

Graham L. Crawford, MSc
Managing Director
Technology Catalysts International UK
Blacksmiths
Clifton Road
Newton Blossomville
Bedford MK43 8AS UK
Telephone: +44 1234 881583
Facsimile: +44 1234 881027
E-mail: gcrawford@technology-catalysts.com

Gerhard Wallenwein, Ph.D.
Managing Director
Laves Chemie Consulting
Antonitergasse 4
D-65812 Bad Soden, Germany
Telephone: +49 6196 62057
Facsimile: +49 6196 27837
E-mail: laveschemie@t-online.de
Website: www.laveschemie.de

Jana Kuhnlova
Managing Director
Inventia s.r.o.
Na Belidle 3
150 00 Praha 5 - Smíchov, Czech Republic
Telephone: +420 2 22247484
Facsimile: +420 2 24218645
E-mail: kuhnlova@inventia.eu
Website: www.inventia.cz

Milos Hrabá
Manager NBD
Inventia s.r.o.
Na Belidle 3
150 00 Praha 5 - Smíchov, Czech Republic
Telephone: +420 2 22247484
Facsimile: +420 2 24218645
E-mail: hraba@inventia.eu
Website: www.inventia.cz

Asia

Sansei Oka
Japanese Business Representative
TCI Japan
4-18-11-101, Takada-Higashi
Kohoku-Ku, Yokohama 223-0065, Japan
Telephone: +81 45 543 5578
E-mail: soka@technology-catalysts.com

Hiromasa Yamamoto
Senior Research Associate
Sumika Technical Information Service Inc.
Tokyo Sumitomo Twin Bldg. (East)
27-1, Shinkawa 2-chome, Chuo-ku
Tokyo 104-0033, Japan
Telephone: +81 3 5543 5875
Facsimile: +81 3 5543 5945
E-mail: hiromasa-yamamoto@ya.sumitomo-chem.co.jp
Website: www.stis.co.jp

Don Ki Kim
President & CEO, Pharmacist
Global Damon Pharma
Suite 1803, Garden Tower Bldg., 98-78
Wooni-Dong, Chongro-Ku
Seoul 110-795, Korea
Telephone: +82 2 3673 2367
Facsimile: +82 2 3673 2369
E-mail: dkkim@gdp.co.kr

Jaison Abraham
General Manager
TCI India
Level 4, Dynasty, 'A' Wing
Andheri-Kurla Road
Andheri East
Mumbai 400 069, India
Telephone: +91 22 4030 9499
Facsimile: +91 22 4030 9199
Mobile: +91 981932 8598
E-mail: jabraham@technology-catalysts.com

R.K. Gupta
Managing Director
Industrial Development Services Pvt. Ltd.
M-1 Kanchenjunga
18 Barakhamba Road
New Delhi 110 001, India
Telephone: +91 11 2 331 2287; 2 331 4714
Facsimile: +91 11 23738227
Email: ids@del2.vsnl.net.in
Website: www.ids-india.org

South America

Carlos A. Massone M.D.
President
Qualia S.A.
Jeronimo Salguero 2533, Piso 12 "A"
1425 Buenos Aires, Argentina
Telephone: +54 11 4807 3433
Facsimile: +54 11 4807 2933
E-mail: carlos.massone@qualia.com.ar
Website: www.qualia.com.ar

NEXT GENERATION SELF-ADMINISTERED DRUG-DEVICE COMBINATIONS: NEW TECHNOLOGIES AND BUSINESS OPPORTUNITIES



TECHNOLOGY AND BUSINESS REVIEW

Visit TCI's website at:
www.technology-catalysts.com

© 2012 Technology Catalysts International

Report Summary

Next-generation drug-device combination products are emerging as a novel mechanism to enhance the delivery of new classes of pharmaceuticals and biologics. Biologics are used to treat chronic conditions including diabetes, cancer, inflammatory diseases, and cardiovascular indications and play a vital role in vaccines. The market for biologics continues to rise with an aging global population, increasing incidence of chronic diseases, and a growing number of products in late-stage development. Biologics are typically administered via injection, which are painful to the patient, require administration from a healthcare professional, and have a high risk of needlestick injury. As a result, companies are developing novel devices to make it easier for patients to administer the drug, improve patient compliance, and to differentiate their product.

As the pharmaceutical market becomes more focused on patient-friendly therapies, self-administration systems using drug-device combination products have become increasingly popular. These products have the potential to reduce costs by allowing the patient to self-administer drugs without a healthcare professional. As a result of this growing trend, companies must focus on patient usability and human factors in order to ensure patient compliance. The most prevalent use of devices is in chronic disease settings, where the patient needs to perform frequent dosing over extended periods of time. These patients would benefit the most from self-administered drug-device combination products. Technologies covered in this report include:

- Autoinjectors and Pen Injectors
- Prefilled Syringes
- Active Transdermal Devices
- Inhalers

The novelty and complexity of drug-device combination products requires companies to face unique challenges in navigating through regulatory channels and bringing products to market. To ensure timely and successful review, companies need to understand the current regulations governing combination products and develop strategies for partnering with the various regulatory agencies during product development and approval.

Key Information Presented

Product and Technology Introduction

- Overview of drug-device combination products
- Advantages and challenges with different drug-device combinations
- Analysis of therapeutic trends

Market Landscape Analysis of Drug-Device Combinations

- Sales of leading drug-device combination products in 2011
- Pipeline products and market forecasts

Regulatory Requirements for Drug-Device Combinations

- Information on US, EU, and Japan regulatory requirements
- Recent published guidance

Technology Licensing Opportunities

- Detailed profiles of drug-device combination technologies
- Updated contact information to initiate licensing agreements

Access Report Online

Technology Catalyst International's newest report, on Next-Generation, Self-Administered Drug-Device Combinations, will be made available online!

Online features include:

- Technology profiles updated in real time
- A searchable database of technology profiles
 - Keyword search
 - Search by company, technology, and route of administration
- Recent news on new product launches, licensing agreements and collaborations

NEXT GENERATION SELF-ADMINISTERED DRUG-DEVICE COMBINATIONS: NEW TECHNOLOGIES AND BUSINESS OPPORTUNITIES

ORDER FORM

☐ Online Subscription ☐ PDF Copy \$3,950.00

Note: All prices are U.S. dollars

Total Amount Due: _____

Shipping/Purchase Information:

Name _____

Title _____

Company _____

Address _____

Telephone _____

Facsimile _____

Email _____

Signature _____

Date _____

☐ Credit Card (☐ MC ☐ Visa ☐ Amex)

Card Number _____

Name on Credit Card _____

Expiration Date _____ Security code (3 or 4 digits) _____

☐ Check enclosed, made payable to Technology Catalysts International

☐ Send invoice to the address above

Wire transfer: please contact TCI directly

Mail, Fax, or Phone your order to:

Ajay Rastogi
Technology Catalysts International Corporation
605 Park Avenue
Falls Church, VA 22046 USA
Telephone: (703) 531-0257
Facsimile: (703) 237-0042
E-mail: arastogi@technology-catalysts.com